Form 4: Voyager Therapeutics Executive Receives Stock Units

Voyager Therapeutics SVP and General Counsel Gregory L. Shiferman was granted 50,000 restricted stock units under the company's 2025 Stock Incentive Plan.

Summary

• Gregory L. Shiferman, SVP and General Counsel at Voyager Therapeutics, Inc., received an award of 50,000 restricted stock units (RSUs).
• These RSUs were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The vesting commencement date for these RSUs is April 1, 2026.
• The RSUs will vest over a three-year period, with one-third vesting on the first anniversary of the commencement date, and the remaining two-thirds vesting in successive one-year increments thereafter.
• Vesting is contingent upon Mr. Shiferman's continued service with the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to an executive, which is typical for companies in this sector and does not inherently signal positive or negative performance.

Positives

• Grant of 50,000 restricted stock units to a key executive, indicating continued investment in management retention and incentivization.
• The RSU award is part of a formal stock incentive plan, suggesting a structured approach to executive compensation.
• The grant is tied to continued service, aligning executive interests with the company's long-term performance.

Risks

• Vesting is contingent on continued employment, meaning the executive could forfeit unvested RSUs if they leave the company before vesting.
• The value of the RSUs is subject to the future performance of Voyager Therapeutics' stock price.

Future Outlook

The future outlook for the granted RSUs is dependent on the continued service of Gregory L. Shiferman and the vesting schedule over three years, as well as the future performance of Voyager Therapeutics' stock.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to senior executives are a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key talent, aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of RSUs is a form of compensation that dilutes existing share ownership slightly upon vesting, but it also serves to retain key management personnel who are expected to drive company value.
• Employees: The RSU grant reinforces the company's use of equity-based compensation, potentially setting a precedent for other employee incentive programs.
• Management: The grant directly benefits Gregory L. Shiferman, aligning his financial interests with the company's stock performance and continued operational success.

Next Steps

• Vesting of restricted stock units over a three-year period, commencing April 1, 2026.
• Continued service by Gregory L. Shiferman to meet vesting requirements.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Stock Options, Restricted Stock Units, RSU, Executive Compensation, Insider Trading, SEC Filing, Gregory L. Shiferman, General Counsel